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S U M M A R Y
Objectives: This study evaluated the efﬁcacy of the pharmacokinetic/pharmacodynamic (PK/PD) index
for increasing the success rate of linezolid treatment based on Monte Carlo simulation, and compared
differences between the calculated PK/PD breakpoints and those deﬁned by committee for critically ill
patients with linezolid treatment.
Methods: A Monte Carlo simulation involving 10 000 subjects was used to analyze the pharmacokinetic
parameters and microbiological data of linezolid for an effectiveness evaluation at the corresponding
AUC24/MIC values (area under the serum concentration–time curve over 24 h/minimum inhibitory
concentration).
Results: As the PK/PD index of linezolid increased from 80 to 120, the corresponding probability of target
attainment (PTA) decreased from 99.91% to 18.97%, with a MIC of 2 mg/l. Furthermore, the cumulative
fraction of response (CFR) reached <90% for several pathogens at an AUC24/MIC of 100–120, revealing a
relatively lower efﬁcacy with recommended linezolid dosing.
Conclusions: These ﬁndings reveal that the target AUC24/MIC value of 80–120 requires further
classiﬁcation for more accurate assessment of the linezolid dose regimen. At a MIC of 2 mg/l, the
clinical outcome varies greatly for different AUC24/MIC values when applying the same dose of linezolid.
In such cases, we suggest optimized adjustment of the linezolid dosage regimen.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Linezolid, the ﬁrst oxazolidinone, is active against antibiotic-
susceptible and antibiotic-resistant Gram-positive bacteria, in-
cluding methicillin-resistant Staphylococcus aureus (MRSA), multi-
drug-resistant Streptococcus pneumoniae, and vancomycin-
resistant enterococci (VRE).1 This antibiotic is an important
therapeutic option for infections caused by resistant Gram-
positive bacterial pathogens in the intensive care unit (ICU).
Linezolid has been approved in many countries for the
management of community-acquired and nosocomial pneumonia,* Corresponding authors. Tel.: +86 29 85323241; fax: +86 29 85323240.
E-mail addresses: zhaoyingren@sohu.com (Y. Zhao),
dongyalin@mail.xjtu.edu.cn (Y. Dong).
http://dx.doi.org/10.1016/j.ijid.2014.01.016
1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International Socomplicated and uncomplicated skin and soft tissue infections, and
infections caused by MRSA and VRE, including cases with concurrent
bacteremia.2,3 However, the emergence of linezolid resistance in
clinical isolates has been reported since 2001.4 A case report of
linezolid-resistant Enterococcus faecium isolated from a patient
without prior exposure to an oxazolidinone appeared in 2002,5
while Scheetz et al.6 established an ecological link between linezolid
consumption and the increasing incidence of enterococci with
decreased susceptibility to linezolid. A relationship was found
between the incidence of genetically proven linezolid resistance
among vancomycin-resistant E. faecium strains and linezolid
consumption. Moreover, Mulanovich et al.7 demonstrated the
emergence of a linezolid-resistant coagulase-negative Staphylococ-
cus strain that was linked to the increased utilization of linezolid.
Signiﬁcant physiological changes may affect the plasma and
tissue pharmacokinetics of linezolid in critically ill patients. Forciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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displayed great inter-individual differences in linezolid interstitial
concentration. Another study provided evidence that linezolid
penetrates the extracellular space ﬂuid to a great extent in septic
patients. Its pharmacokinetic proﬁle in plasma and tissues is
comparable in ICU patients, which may result in an unexpected
therapeutic effect with conventional therapy.9 All of these reports
demonstrate that the evaluation and optimization of the current
trend of linezolid use for critically ill patients has become an
unavoidable issue.
The application of simulation and simulation-based
approaches, such as Monte Carlo simulation, is currently increas-
ing in most therapeutic areas. These methods examine detailed
information regarding the time course of drug effects and the
probability of target attainment (PTA).10,11 In the case of linezolid,
Monte Carlo simulation is required to optimize the dosing regimen
in critically ill patients, to optimize the clinical outcome, and to
minimize the development of resistance, especially in cases where
there is limited pharmacodynamic information.12,13 Given the
uncertainty of the pharmacokinetic proﬁle of individual severely ill
patients and the distribution of the minimum inhibitory concen-
tration (MIC) in early treatment, Monte Carlo simulation can be
implemented to evaluate the linezolid dosage regimen to achieve
the expected pharmacokinetic/pharmacodynamic (PK/PD) target
for successful therapy. Therefore, the purpose of this study was to
utilize the PK/PD model and Monte Carlo simulation to evaluate
the success probability of an expected clinical outcome for
infections caused by different bacteria in critically ill patients. In
addition, differences were investigated among the calculated
susceptibility breakpoints and the susceptibility breakpoints
deﬁned by the Clinical and Laboratory Standards Institute (CLSI)
and the European Committee on Antimicrobial Susceptibility
Testing (EUCAST).
2. Methods
The methodology included: (1) acquisition of pharmacoki-
netic parameters and microbiological information, (2) Monte
Carlo simulation, (3) calculation of an estimate of the PTA
(deﬁned as the probability that at least a speciﬁc value of PK/PD is
achieved at a certain MIC), and (4) calculation of the cumulative
fraction of response (CFR; deﬁned as the expected population
PTA for a speciﬁc drug dose and a speciﬁc population of
microorganisms).14
2.1. Acquisition of pharmacokinetic parameters and microbiological
information
The pharmacokinetic parameters of linezolid were obtained
from published studies. Pharmacokinetic studies were identiﬁed
using PubMed, the National Library of Medicine search engine for
the Medline database, with the following keywords linezolid,
pharmacokinetics, population pharmacokinetics, critically ill
patient, and ICU. Studies were included if they evaluated
clinically relevant dosing regimens and provided the means
for the pharmacokinetic parameters of interest with the
corresponding variability. Data were obtained from the EUCAST
MIC distribution website (http://www.eucast.org; last accessed
April 10, 2013).
2.2. Pharmacokinetic/pharmacodynamic analyses and Monte Carlo
simulation
2.2.1. Estimation of the PTA
The pharmacokinetic parameters were deﬁned as a log-normal
distribution in the Monte Carlo simulation, and in the case of MIC, adiscrete distribution based on EUCAST data was considered. A
Monte Carlo simulation with 10 000 subjects was performed using
Crystal Ball software (Fusion Edition, version 11.1.1.1.00, Oracle).
The area under the serum concentration–time curve over 24 h
(AUC24) data for linezolid were evaluated with the dose regimen of
600 mg every 12 h (q12 h). The success rate for linezolid in
critically ill patients may be higher for AUC24/MIC values between
80 and 120.15 The PTA was calculated over a range of doubling
MICs between 0.008 and 64 mg/l using the following equation:
AUC24/MIC = (D  24)/(MIC  t  CLt), where D is the dose of
antibiotic administered (mg), t is the dosing interval (h), and CLt is
the total body clearance (l/h).16 The corresponding PTA was
calculated at a ﬁxed MIC value in the range 0.008–64 mg/l.
2.2.2. Calculation of the CFR
CFR is deﬁned as the expected population PTA for a speciﬁc drug
dose and a speciﬁc population of microorganisms16 and pertains to
the success probability for a treatment without clinical suscepti-
bility of the isolated pathogen. The PTA was included in the
calculation for each MIC and for the MIC distribution of the
bacterial population. Calculation of the CFR was achieved using the
data from the corresponding MIC distribution, whereby CFR values
of >90% represent an optimal regimen achieved against a
population of organisms.
2.2.3. Comparison of susceptibility breakpoints
PK/PD breakpoints were set at the highest MIC value with a
bactericidal target attainment of 90%, as this is the accepted
target attainment cutoff currently used by the CLSI when
determining MIC breakpoints.17 The classiﬁed PK/PD breakpoints
were then compared with those published by the CLSI (M100-S22)
and EUCAST (version 3.1) for 2012 to evaluate the impact of
discrepancies on the normal Gram-positive pathogen susceptibili-
ty of critically ill patients.
3. Results
3.1. Evaluation of the PTA and CFR
Table 1 gives the MIC probability distribution of selected Gram-
positive pathogens in critically ill patients based on EUCAST data.
The distributions are based on collated data from a total of 181 634
MIC distributions from worldwide sources. The distributions
include MICs from national and international studies such as
resistance surveillance programs, as well as MIC distributions from
published articles, the pharmaceutical industry, veterinary pro-
grams, and individual laboratories. For enterococci, 100% of the
whole isolates for linezolid presented MICs of 32 mg/l, with
95.26% of the Enterococcus faecalis isolates exhibiting MICs of 2
mg/l. Nearly half of E. faecium isolates (55.41%) exhibited a high
level of susceptibility to linezolid, with a MIC of 2 mg/l. Moreover,
32.22% of E. faecium isolates had a MIC of 1 mg/l. Similarly, 46.07%
and 43.34% of E. faecalis isolates presented MICs of 1 and 2 mg/l for
linezolid, respectively. For staphylococci, almost all of the
pathogens had MICs of 2 mg/l for linezolid, among which MRSA
(98.76%) and methicillin-sensitive S. aureus (MSSA; 99.47%) had a
MIC of 2 mg/l. With regard to streptococci, all of the isolates
presented with MICs of 8 mg/l, demonstrating a high suscepti-
bility to linezolid.
Figure 1 shows the PTA (%) calculated by PK/PD analysis and
Monte Carlo simulation at MIC values in the range 0.008–64 mg/l
for a linezolid dose regimen of 600 mg q12 h. With the change of
MIC value in critically ill patients, the corresponding PTA value
varied signiﬁcantly at the targeted AUC24/MIC values of between
80 and 120. PTA values were 100% with MICs of 1 mg/l and an
AUC24/MIC ranging from 80 to 120. However, for AUC24/MIC values
Table 1
Frequency distribution of the MIC of linezolid for the selected pathogens from the EUCAST MIC distribution website
MIC (mg/l) n 0.064 0.125 0.25 0.5 1 2 4 8 16 32 SB
(mg/l)
Enterococci
Enterococcus faecalis 8336 0.18 0.43 5.24 46.07 43.34 4.57 0.07 0.04 0.06 4
Enterococcus faecium 5214 0.17 0.52 7.15 32.22 55.41 4.35 0.15 0.02 4
Staphylococci
Staphylococcus aureus 62 420 0.01 0.18 0.29 2.60 31.92 58.72 6.22 0.04 0.01 0.002 4
MRSA 404 0.74 98.76 0.25 0.25 4
MSSA 571 0.53 99.47 4
Staphylococcus capitis 282 1.77 3.55 24.47 60.28 9.93 4
Staphylococcus coagulase-negative 6371 0.06 0.13 1.02 8.74 65.34 22.98 1.73 4
Staphylococcus coagulase-negative MRSE 528 4.17 89.02 6.63 0.19 4
Staphylococcus epidermidis 7270 0.06 0.56 5.16 28.58 54.26 10.98 0.37 0.01 0.01 4
Staphylococcus epidermidis MSSE 84 9.52 79.76 10.71 N/A
Staphylococcus haemolyticus 1185 0.17 2.95 29.87 59.16 7.43 0.34 0.08 4
Staphylococcus hominis 669 0.15 0.15 2.54 17.19 73.24 6.28 0.15 0.15 0.15 4
Staphylococcus lugdunensis 57 1.75 28.07 59.65 10.53 4
Staphylococcus saprophyticus 142 4.93 46.48 42.96 5.63 4
Staphylococcus warneri 148 0.68 14.86 72.30 11.49 0.68 4
Streptococci
Streptococcus agalactiae 2084 0.24 5.47 80.57 13.53 0.19 2
Streptococcus anginosus 138 0.72 10.14 76.81 12.32 2
Streptococcus bovis 130 0.77 14.62 65.38 19.23 2
Streptococcus constellatus 74 1.35 6.76 40.54 50.00 1.35 2
Streptococcus group C 149 2.01 0.67 8.05 82.55 6.71 2
Streptococcus group G 674 2.08 82.20 14.24 1.48 2
Streptococcus mitis 201 0.50 1.49 20.40 75.62 1.99 2
Streptococcus oralis 278 14.39 78.42 6.83 0.36 2
Streptococcus pneumoniae 60 080 0.02 0.05 0.96 7.67 65.33 25.93 0.03 2
Streptococcus pyogenes 23 294 0.05 1.08 1.21 12.32 67.22 18.06 0.06 0.004 2
Streptococcus sanguinis 96 1.04 23.96 71.88 3.13 2
Streptococcus, viridans group 755 0.79 10.60 73.51 15.10 2
MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; SB, susceptibility breakpoint; MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; MSSE, methicillin-susceptible
Staphylococcus epidermidis; N/A, not available.
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18.97%, respectively, at a MIC of 2 mg/l. Furthermore, the PTA value
was always zero for one ﬁxed AUC24/MIC target value ranging from
80 to 120 when presenting with a MIC >4 mg/l.
Table 2 lists the data from the assessment of CFR (%) for a standard
linezolid dosing regimen evaluated based on three AUC24/MIC
values (80, 100, and 120). At the low AUC24/MIC value of 80, the
corresponding CFRs of E. faecium, E. faecalis, and the majority of
staphylococci (including MRSA and MSSA) and streptococci were
higher than 95%; exceptions were S. aureus (93.68%) and Staphylo-
coccus saprophyticus (94.33%). At the moderate AUC24/MIC value ofFigure 1. Probability of target attainment as a function of the MIC for 10100, the corresponding CFRs of E. faecium (86.21%), E. faecalis
(88.01%), and some staphylococci including S. aureus (83.91%), MRSA
(82.99%), MSSA (83.37%), and S. saprophyticus (87.18%) were all
lower than 90%; the remainder all attained optimization, with CFR
values of >90%. At a high AUC24/MIC value of 120, the corresponding
CFRs of E. faecium (50.58%), E. faecalis (60.14%), and several
staphylococci and streptococci isolates were <80%, among which
those of MRSA and MSSA had decreased markedly to <20%. Other
isolates, such as Streptococcus constellatus, and Streptococcus mitis,
still presented CFR values higher than 90%, theoretically attaining
the expected clinical outcome. 000 simulated subjects given linezolid. The target was AUC24/MIC.
Table 2
Expected cumulative fraction of response (CFR) for linezolid. The chosen targets were AUC0–24/MIC of 80, 100, and 120
Linezolid (600 mg every 12 h) Probability (%)
AUC24/MIC = 80 AUC24/MIC = 100 AUC24/MIC = 120
Enterococci
Enterococcus faecalis 95.22 88.01 60.14
Enterococcus faecium 95.42 86.21 50.58
Staphylococci
Staphylococcus aureus 93.68 83.91 46.15
MRSA 99.42 82.99 19.48
MSSA 99.91 83.37 19.40
Staphylococcus capitis 99.99 98.34 91.95
Staphylococcus coagulase-negative 98.25 94.43 79.65
Staphylococcus coagulase-negative MRSE 99.80 98.70 94.44
Staphylococcus epidermidis 99.59 97.77 90.71
Staphylococcus epidermidis MSSE 99.99 98.21 91.32
Staphylococcus haemolyticus 99.57 98.34 93.56
Staphylococcus hominis 99.55 98.50 94.46
Staphylococcus lugdunensis 99.99 98.24 91.47
Staphylococcus saprophyticus 94.33 87.18 59.56
Staphylococcus warneri 99.31 97.40 90.02
Streptococci
Streptococcus agalactiae 99.80 97.55 88.84
Streptococcus anginosus 99.99 97.94 90.02
Streptococcus bovis 99.98 96.78 84.42
Streptococcus constellatus 100.00 99.77 98.91
Streptococcus group C 99.99 98.88 94.56
Streptococcus group G 98.50 96.13 86.97
Streptococcus mitis 100.00 99.67 98.39
Streptococcus oralis 99.63 98.50 94.10
Streptococcus pneumoniae 99.95 95.64 78.96
Streptococcus pyogenes 99.92 96.92 85.31
Streptococcus sanguinis 100.00 99.48 97.47
Streptococcus, viridans group 99.99 97.48 87.77
AUC24, area under the serum concentration–time curve over 24 h; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; MSSE, methicillin-susceptible Staphylococcus epidermidis.
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susceptibility interpretations
Table 3 lists the PK/PD breakpoints calculated at classiﬁed
values of AUC24/MIC, and those deﬁned by EUCAST and the CLSI.
PK/PD breakpoints are expressed as the highest MIC value, with
bactericidal target attainments of 90% as the accepted target
attainment cutoff currently used by the CLSI when determining
MIC breakpoints. The PK/PD breakpoints of enterococci and
staphylococci were lower than those deﬁned by EUCAST and the
CLSI at an AUC24/MIC value of 80, while that of streptococci was
similar to those quoted by EUCAST and the CLSI. At AUC24/MIC
values of 100 and 120, the PK/PD breakpoints of enterococci,
staphylococci, and streptococci were all lower than those deﬁned
by EUCAST and the CLSI. Differences between the breakpoints
obtained by PK/PD analysis and those deﬁned by EUCAST and the
CLSI were generally within one or two doubling dilutions; for
example, the PK/PD breakpoint of staphylococci in the present
study was 1 mg/l, while that published by EUCAST and the CLSI
was 4 mg/l.Table 3
Comparison of probability of target attainment (PTA, %) and breakpoints (mg/l) of 
Antimicrobial Susceptibility Testing (EUCAST), and Clinical and Laboratory Standards I
Linezolid
(600 mg every 12 h)
PK/PD breakpoint
(PTA, %)
Enterococci Stap
EUCAST
(PTA, %)
CLSI
(PTA, %)
EUC
(PTA
AUC24/MIC = 80 2 (99.91) 4 (0.01) 2 (99.91) 4 (0
AUC24/MIC = 100 1 (100) 4 (0) 2 (83.28) 4 (0
AUC24/MIC = 120 1 (100) 4 (0) 2 (18.97) 4 (0
AUC24, area under the serum concentration–time curve over 24 h; MIC, minimum inh
a IE, insufﬁcient evidence that the species in question is a good target for therapy wWhen there was coincidence between the published EUCAST,
CLSI, and PK/PD breakpoints, the success likelihood was high (PTA
90%) at breakpoints set by international committees. However,
when the CLSI or EUCAST breakpoints were higher than those
calculated by PK/PD analysis, low PTA values were observed at
breakpoints set by international committees.
4. Discussion
The pharmacokinetic proﬁles of critically ill patients are
affected by pathophysiological and clinical factors, and may
change signiﬁcantly after linezolid administration.18–20 In addi-
tion, Gram-positive pathogens (e.g., enterococci, staphylococci,
and streptococci) are common aerobic bacteria that are isolated
from critically ill patients with nosocomial infections. Inappropri-
ate treatment is thus likely to result in a high clinical failure rate,
high mortality, increased cost, increased toxicity, and increased
resistance. Therefore, the use of an optimized dosing regimen that
guarantees an optimal concentration of linezolid at the infection
site is essential for optimizing the clinical outcome. Knowledge ofthe pharmacokinetic/pharmacodynamic (PK/PD) index, European Committee on
nstitute (CLSI) for Gram-positive cocci
hylococci Streptococcus
pneumoniae
Other streptococci
AST
, %)
CLSI
(PTA, %)
EUCAST
(PTA, %)
CLSI
(PTA, %)
EUCAST
(PTA, %)
CLSI
(PTA, %)
.01) 4 (0.01) 2 (99.91) 2 (99.91) IEa 2 (99.91)
) 4 (0) 2 (83.28) 2 (83.28) IE 2 (83.28)
) 4 (0) 2 (18.97) 2 (18.97) IE 2 (18.97)
ibitory concentration.
ith the drug.
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organisms exhibiting one ﬁxed MIC to linezolid is relevant to
optimal selection. In this regard, Monte Carlo simulation can be
used as a statistical tool for estimating how selected AUC24/MIC
values inﬂuence the PTA associated with linezolid efﬁcacy and the
expected population PTA for conventional linezolid dosing and a
speciﬁc population of microorganisms.
In this work, we evaluated the PTA in critically ill patients with
MIC ranging from 0.008 mg/l to 64 mg/l using the dose of linezolid
600 mg q12 h by PK/PD analysis and Monte Carlo simulation. The
corresponding PTA value varied signiﬁcantly according to the MIC.
The PTA ﬁndings revealed that the empirical linezolid dose
regimen was appropriate for critically ill patients with a MIC of
1 mg/l. The same linezolid dosage was less effective among
patients with a MIC of 2 mg/l at an AUC24/MIC value of 100 or 120
for predicting the required optimized linezolid use.
Moreover, the CFR with standard linezolid dosing was
evaluated for different AUC24/MIC target values. Theoretically,
the best treatment outcome for E. faecium, E. faecalis, and
staphylococci including S. aureus, MRSA, MSSA, and S. saprophy-
ticus was achieved at an AUC24/MIC value of 80. However, for an
AUC24/MIC value of 100 the CFR for the aforementioned isolates
decreased to between 80% and 90%, representing a moderate
probability of a successful clinical outcome. Therefore, it appears
that the clinician must carefully monitor the patient’s condition
when administering therapeutic drugs. At the target AUC24/MIC
value of 120, the CFR was consistently below 80% for E. faecium, E.
faecalis, and staphylococci including S. aureus, MRSA (CFR <20%),
MSSA (CFR <20%), and S. saprophyticus, indicating a lower success
probability for infection. The selection of new drugs or adjustment
of the present dosing regimen should be considered in such cases.
The present results diverge from the previously predicted high
success probability at the recommended AUC24/MIC target of 80–
120.15 Thus, the target AUC24/MIC value requires further classiﬁ-
cation to enable a more accurate assessment of linezolid dose
regimens in particular groups of patients.
The present study also evaluated discrepancies between the PK/
PD breakpoints and those deﬁned by EUCAST and the CLSI. The PK/
PD breakpoints found herein were generally markedly lower than
those deﬁned by the CLSI or EUCAST. As a result, high success
clinical probabilities (>90%) were obtained when there was
coincidence between EUCAST and CLSI breakpoints and the
calculated one; nevertheless, an isolate will be considered of high
susceptibility for present linezolid use based on CLSI and EUCAST
breakpoints, whilst the calculated breakpoint predicts clinical
failure. This may explain the clinical failure of treatments with
recommended linezolid doses against microorganisms that are
considered susceptible.21,22 Similar results were noted by Ası´n
et al.,23 who pointed out that the PK/PD breakpoints of linezolid
were lower than all of those deﬁned by EUCAST and the CLSI. In
their study, a ﬁxed AUC24/MIC value of 100 was chosen for
linezolid PTA and CFR evaluation according to pharmacokinetic
parameters from healthy adult volunteers. However, no differ-
ences in breakpoints at an AUC24/MIC value of 80 were found for
linezolid against some enterococci, staphylococci, and streptococci
in our present work. Compared with the published study, our
improvement of targeted AUC24/MIC classiﬁcation (AUC24/MIC =
80, 100, and 120) was employed for more accurate assessment of
linezolid administered in critically ill patients. Therefore, the effect
of a variable targeted AUC24/MIC value on linezolid clinical success
probabilities and PK/PD breakpoints should be taken into
consideration.
Some limitations of this study should be considered. First, the
statistical simulation in this work was based on data from serum
pharmacokinetics; these ﬁndings are thus best suited to blood-
stream infections, with the associated relatively narrow scope ofapplication. The application of these ﬁndings to other sites of
infection such as in the respiratory tract may result in a poor
clinical outcome or even no response to therapy. Second, the local
MIC distribution must be considered and must be updated
periodically because of the emergence of regional drug resistance
and the huge regional differences in MIC distribution. Limitations
also exist with regard to current PK/PD modeling of the predicted
clinical outcome. Prospective experiments including pharmacoki-
netic analysis, antimicrobial susceptibility, and clinical data are
indispensable and will help in accurately determining the
correlations between MIC breakpoints and clinical results.
In conclusion, based on the present ﬁndings and limitations, we
can draw the following conclusions: (1) With MICs of 1 mg/l, a
good clinical outcome was predicted with the standard linezolid
dosing regimen at an AUC24/MIC value of 80–120, whilst at MICs of
2 mg/l, the clinical outcome varied according to the AUC24/MIC
value for the same dose of linezolid. Thus, optimization of the
current linezolid dosing regimen is necessary to improve
treatment efﬁcacy. (2) The target AUC24/MIC value of 80–120
requires further classiﬁcation to enable a more accurate assess-
ment of the linezolid dosing regimen in critically ill patients.
Regarding recommendations for linezolid in the later course of
treatment for infection, the decision as to whether empirical
linezolid treatment should be maintained or adjusted should be
based on multiple categories of AUC24/MIC ratios. (3) Finally, the
ﬁndings of this study reinforce the proposal that increasing the
probability of successful clinical treatment for critically ill patients
requires not only consideration of the antimicrobial MIC distribu-
tion, but also the PK/PD index of AUC24/MIC ratios.
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